ABUS vs KMB · P/E 5.4, rev $6.2M vs P/E 19, rev $20.06B
Arbutus Biopharma Corp (ABUS) versus Kimberly-Clark Corporation (KMB) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Kimberly-Clark Corporation (KMB) is a household & personal products company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported KMB revenue for 2024-12-31 was $20.06B. Net income was $2.58B. Revenue was down 1.8% from 2023-12-31 to 2024-12-31. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. KMB currently screens at market cap $32.88B and trailing P/E 19.2.
Not investment advice. Open the ABUS and KMB stock pages for the full models.
Not investment advice.